Drug Profile
Pamrevlumab - FibroGen
Alternative Names: Anti-CTGF antibody - FibroGen; FG-3019Latest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator FibroGen
- Class Antifibrotics; Antineoplastics; Antivirals; Cardiovascular therapies; Immunotherapies; Monoclonal antibodies; Urologics
- Mechanism of Action Connective tissue growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Duchenne muscular dystrophy; Idiopathic pulmonary fibrosis; Pancreatic cancer
- Phase II/III COVID 2019 infections
- Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies; Glioblastoma; Glomerulonephritis; Hepatic fibrosis
Most Recent Events
- 08 Dec 2023 FibroGen terminates phase III ZEPHYRUS-2 trial in Idiopathic Pulmonary Fibrosis (IPF) in US, Hong Kong, Taiwan, Argentina, Australia, Chile, China, Japan, South Korea and Russia, due to study does not meet its primary endpoint (NCT03955146)
- 29 Sep 2023 Fibrinogen terminates the phase III LELANTOS-1 trial in Duchenne muscular dystrophy (In adolescents, In adults, In the elderly, Combination therapy, In Children) in USA, Australia, Austria, Belgium, Canada, China, Czech Republic, France, Israel, Italy, Netherlands, Spain, Switzerland and the UK (IV) (NCT04371666)
- 27 Sep 2023 FibroGen terminated the phase II trial in Duchenne muscular dystrophy (In adolescents, In adults) in USA (IV) due to sponsor's decision (NCT02606136)